ALX Oncology Reveals Durable CD47 Blocker Responses in HER2-Positive Gastric Cancer at ASCO-GI 2 years ago AnaIn Pharma Industry UpdatesStartupsTop Stories
Oncolytics Biotech To Reveal New Pelareorep Efficacy and Safety Data at ASCO-GI for Anal and Pancreatic Cancers 2 years ago AnaIn BreakthroughsClinical TrialsTop Stories
Dogwood Therapeutics Begins Phase IIb Dosing of Halneuron® for Chemotherapy-Induced Neuropathic Pain 2 years ago AnaIn BreakthroughsClinical Trials
Nature Highlights Self-Driving Labs and Advanced Immunotherapies Among Top Technologies to Watch in 2025 2 years ago AnaIn BreakthroughsClinical TrialsTechnology
GSK’s Jemperli Receives EMA Approval for First-Line Endometrial Cancer Treatment 2 years ago AnaIn Clinical TrialsFeatured AnalysisLeadersPharma Industry Updates
FDA Accepts Arrowhead’s New Drug Application for Plozasiran in Treating Familial Chylomicronemia Syndrome 2 years ago AnaIn Biopharma HighlightsFDA Approvals
FDA Approves Datopotamab Deruxtecan (Datroway) for HR-Positive, HER2-Negative Breast Cancer 2 years ago AnaIn FDA ApprovalsInnovationLeadersResearch Updates
Evaxion Completes Dosing in Phase II Trial of Personalized Cancer Vaccine EVX-01, Paving the Way for AI-Driven Oncology 2 years ago AnaIn AI & DataBreakthroughsClinical Trials
Avance Clinical Captures Australia’s Early-Phase CRO Market, While Idorsia Prepares Strategic Pivot at JPM Week 2 years ago AnaIn Biopharma HighlightsResearch UpdatesStartups
FDA Grants Rare Pediatric Designation to ViGeneron’s RP Gene Therapy VG901; EMA Pushes for EU Clinical Trials Transition 2 years ago AnaIn BreakthroughsClinical TrialsResearch Updates
Denali, Agios, Cabaletta and Walden Drive Rare Disease and Immuno-Innovations into the Spotlight at JP Morgan Week 2 years ago AnaIn Breaking NewsBreakthroughsIndustry ConferencesLeadersPeopleTop Stories
Mereo BioPharma Advances Rare Disease Programs with Setrusumab and Alvelestat Milestones 2 years ago AnaIn Biopharma HighlightsBreakthroughsTop Stories
Bio-Path Holdings Gears Up for Dual Progression of Oncology and Obesity Programs in 2025 2 years ago AnaIn Industry ConferencesPeopleResearch Updates
J.P. Morgan Healthcare Conference 2025 Opens with Heavy Security, Heightened Stakes, and Hints of Revival in Biopharma Deal-Making 2 years ago AnaIn Industry ConferencesPeoplePharma Industry Updates
Hoyos Therapeutics Unveils Inhaled mRNA Gene-Silencing Therapy in Landmark Clinical Trial for Asthma 2 years ago AnaIn Top Stories
